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Betaine supplementation decreases post-methionine hyperho- mic [3]. This is thought to contribute to the common
mocysteinemia in chronic renal failure. occurrence and rapid progression of atherosclerosis in
Background: Fasting and post-methionine load hyperhomo- the ESRD population. Although there is no evidencecysteinemia are independent risk factors for vascular disease
yet to show that lowering plasma tHcy reduces the riskthat are common in chronic renal failure. Folate decreases but
seldom normalizes fasting total homocysteine (tHcy) concen- of atherosclerosis, it is widely believed that reducing
trations in such patients. Glycine betaine (GB) is known to tHcy levels should be a therapeutic target [4].
decrease tHcy in other clinical settings, but whether it is bene- The optimal treatment for hyperhomocysteinemia inficial in chronic renal failure has not been established.
chronic renal failure has not been determined. Folic acidMethods: We conducted a crossover-controlled trial in 36
patients with chronic renal failure to determine if oral GB 5 to 10 mg daily decreases fasting tHcy by 30 to 50%,
decreased fasting or post-methionine tHcy concentrations. All but even doses of 60-mg folate seldom normalize tHcy
subjects received, in randomized sequence, 5-mg folic acid and in ESRD [5]. N,N,N-trimethylglycine [glycine betaine50-mg pyridoxine daily, with or without GB 4-g daily, for three
(GB)] has been shown to decrease fasting plasma tHcymonths each. Fasting plasma tHcy, GB, folate, B vitamins,
concentrations in people with severe hyperhomocys-serum lipids and creatinine were measured at one and three
months, and methionine load tests were performed at the end teinemia due to cystathionine -synthetase deficiency [6]
of each three-month treatment phase. and in healthy volunteers [7]. Conversely, van Guldener
Results. GB and N,N-dimethylglycine (DMG) levels in plasma
et al found that GB did not decrease tHcy in hemodialy-and urine increased markedly during GB treatment. Fasting
sis patients [8]. The effect of GB in mild-to-moderatetHcy decreased from baseline with both treatments but did not
differ between treatments. Post-methionine tHcy decreased with chronic renal failure has not been studied. This is perti-
both treatments and was 18% lower on GB than on folate and nent because for tHcy-lowering therapy to have any im-
pyridoxine alone (P  0.001). There were small increases in
pact on the incidence of atherosclerosis in ESRD itlipids during treatment with GB but the ratio of total: HDL
would presumably need to start well before dialysis ischolesterol was unchanged.
Conclusions. GB supplementation had no effect on fasting required.
tHcy in patients with chronic renal failure who were folate and The aim of this study was to determine whether glycine
pyridoxine replete, but it significantly decreased tHcy concen-
betaine further reduces tHcy concentrations in subjectstrations after methionine loading.
with chronic renal failure who are on folate and pyridox-
ine therapy. Both fasting and post-methionine load tHcy
concentrations were studied because each has been inde-An elevated plasma homocysteine concentration is an
pendently associated with an increased risk of vascularindependent risk factor for atherosclerotic disease [1, 2].
disease [9].Plasma total homocysteine (tHcy) increases as renal
function declines and more than 80% of people with
end-stage renal disease (ESRD) are hyperhomocysteine-
METHODS
Patients
Key words: atherosclerosis, homocysteine, folic acid, pyridoxine, me-
thionine, vascular renal disease, end-stage renal disease. The Canterbury Ethics Committee approved the study
protocol. It was a prospective, open label, crossover-
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given as two divided doses dissolved in 100 to 200 mL Methionine load
water. A methionine load test was done at baseline and at the
Treatment B. Folic acid 5 mg and pyridoxine 50 mg/ end of each three-month treatment phase. After venous
day only. blood was drawn for fasting plasma tHcy concentrations
Each treatment was administered for three months. the patients drank 0.1 g/kg of l-methionine dissolved in
Subjects then switched to the other treatment for a fur- 100 mL orange juice. They were also given a snack of
ther three months. There was no washout period be- one jam sandwich. They took no other food until their
tween treatments and their order was randomized ac- return four hours later, when a repeat venous sample
cording to computer-generated random numbers. for plasma tHcy was taken. The plasma tHcy of both
It was estimated that 35 subjects would be necessary samples was measured as above and in the same assay
batch.to detect a 10% difference in fasting plasma tHcy concen-
trations between treatments (  0.05,   0.8). Patients
Glycine betaine and dimethylglycinewith a plasma creatinine of 0.14 to 0.4 mmol/L were
The same assay was used to measure GB and DMGidentified from our clinical database (Proton; Clinical
in plasma and urine. Blood was collected into EDTAComputing Ltd, London, UK). Diabetics, those with sig-
tubes and separated immediately. The separated plasmanificant recent illnesses, vitamin B12 deficiency or taking
was stored at 20C until analysis. Concentrations forfolate or B vitamin supplements, were excluded. Letters
DMG and GB were measured by high performance liq-of invitation were sent to 95 patients and 37 agreed to
uid chromatography (HPLC) using a method adaptedparticipate. Nineteen were randomly assigned to start
from Lever et al [10]. The compounds were extractedtreatment A, eighteen began treatment B (one withdrew
into 10% methanol in acetonitrile and were then deriva-within one month) and 36 completed the study. These
tized with 2-naphthacyltriflate [11]. Separation of the36 (23 male, all Caucasian) were aged 63.8 2.3 (mean
derivatives was performed using HPLC on a 250-4 (5SEM), range 40 to 77 years, and their plasma creatinine
m) alumina column (Aluspher; Merck, Darmstadt,was 0.24  0.02 mmol/L. The cause of their renal fail-
Germany) and with ultraviolet (UV) detection (wave-ure was glomerulonephritis (27%), polycystic kidney dis-
length 249 nm). The mobile phase contained 10 mmol/Lease (17%), hypertensive nephrosclerosis (25%), ob-
succinic acid and 3.7 mmol/L triethylamine in acetoni-structive nephropathy (8%), reflux nephropathy (6%),
trile. Standards were used to quantify HPLC peaks andother causes or unknown (17%). Ten patients had estab-
spiked plasma samples were used to determine plasmalished vascular disease, three were smokers and four
recoveries, which were always over 90%. The inter- andtook statins for hypercholesterolemia, at a constant dose
intra-assay coefficients of variation were less than 8%.
throughout.
Patients were seen each month and monitored for side Lipids
effects. Compliance was evaluated by pill count and by Plasma total cholesterol, high-density lipoprotein (HDL)
measurement of blood levels. At baseline, one and three cholesterol and triglycerides were measured by a com-
months in each phase blood was drawn after a 14-hour mercial enzyme assay (Aeroset; Abbott). Low-density
overnight fast for measurement of routine biochemistry lipoprotein (LDL) cholesterol was calculated using the
(Aeroset; Abbott, North Chicago, IL, USA), hematology Friedwald formula [12] modified to SI units (LDL 
(Coulter counter; Coulter Electronics, Hialeah, FL, USA), total cholesterol  HDL  0.45 	 triglycerides).
tHcy, lipids, vitamin levels, plasma GB and N,N-dimeth-
ylglycine (DMG) concentrations. Mid-stream urine sam- Folate and vitamin B12
ples were collected for creatinine, GB and DMG concen- Serum vitamin B12 was measured by a commercial
trations. Laboratory staff members were blinded to the chemiluminescence assay (ACS: 180; Chiron Diagnos-
patients’ treatment sequence. tics, Medfield, MA, USA). Folate was measured on a
hemolysate of 25 L whole blood in 0.5 mL ascorbic
Plasma homocysteine acid by chemiluminescence and red blood cell (RBC)
Venous blood was collected into chilled ethylenedi- folate was calculated as: Folate (RBC) [Folate (hemo-
aminetetraacetic acid (EDTA) tubes, centrifuged imme- lysate) 	 21] 
 [hematocrit].
diately and the plasma frozen at 20C until analysis.
PyridoxineThe plasma tHcy concentration was measured within
two weeks of collection using a commercial fluorescent Pyridoxal-5-phosphate was extracted from heparin-
polarization immunoassay (IMX; Abbott). The assay ized blood with hydrochloric acid and derivatized with
was subject to regular quality control and had an inter- semicarbazide. The semicarbazide derivative was sepa-
rated by HPLC with post-column adjustment of the elu-assay variability (coefficient of variation) of 4%.
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Table 1. Baseline values and correlations with fasting plasma homocysteine (N  36)
Variable Mean  SEM Reference range Correlation (r) Significance
Age years 63.82.3 — 0.27 0.11
Fasting tHcy lmol/L 18.70.99 5–15 1.0 —
Post-methionine tHcy 45.32.7 21–56 0.58 0.001
Creatinine mmol/L 0.240.02 0.12 0.34 0.05
RBC folate nmol/L 90686 380–1200 0.14 0.41
Serum B12 pmol/L 37239 120–450 0.32 0.06
Vitamin B6 nmol/L 5621 35–107 0.16 0.34
Plasma GB lmol/L 29.32.1 20–63 0.13 0.46
Plasma DMG lmol/L 8.00.59 1.3–5.9 0.23 0.18
Plasma DMG:GB 0.310.03 0.03–0.29 0.33 0.05
Total cholesterol mmol/L 5.870.22 3.2–5.2 0.19 0.28
Triglycerides mmol/L 1.980.17 0.3–1.5 0.26 0.13
HDL cholesterol mmol/L 1.260.08 1.04–1.30 0.41 0.05
Abbreviations are: tHcy, total homocysteine; RBC, red blood cell; GB, glycine betaine; DMG, N,N-dimethylglycine; HDL, high-density lipoprotein.
ate to pH 10 and fluorescence monitoring at 365 nm/460
nm (Instruchemie, Hilversum, The Netherlands).
Statistics
Statistical analysis was performed using SPSS statis-
tical software. Changes with treatment were analyzed by
repeated measures analysis of variance (ANOVA) with
treatment sequence considered for possible between-
subject differences. Baseline comparisons between treat-
ment groups were made using the Student t or Mann-
Whitney tests and Pearson’s test determined correlations
with tHcy. Results with P values less than 0.05 were
considered statistically significant. Data are presented as
mean  SEM, unless otherwise stated.
RESULTS
Complete data were obtained for the 36 patients who
completed the study. No adverse effects were reported.
There were no significant differences at baseline between
those starting treatment A or B. The sequence of treat-
ments had no effect on any of the variables measured
and there were no carryover effects after the treatment
crossover. In particular, the effect of treatment sequence
on both the fasting (P  0.46) and post-methionine
plasma tHcy concentration (P  0.356) was not signifi-
Fig. 1. Fasting and post-methionine plasma homocysteine concentra-cant. All patients had baseline RBC folate and serum tions with treatment A (folate/B6/betaine) and treatment B (folate/B6
B12 concentrations within the reference range for the only), in group 1 (A; N 19) and group 2 (B; N 17). Data are mean
SEM. aP 0.001 for post-methionine tHcy vs. baseline and vs. treatmentlaboratory. Vitamin B6 was below the normal range in B; bP  0.001 for post-methionine tHcy vs. baseline and vs. treatment
12 patients, and 5 had low plasma GB concentrations. A; cP  0.001 for fasting tHcy on both treatments vs. baseline. 
represents fasting plasma tHcy concentrations.Twenty-five patients had elevated plasma DMG and
tHcy concentrations (tHcy15 mol/L). Significant cor-
relates with baseline fasting tHcy were plasma creatinine,
the plasma DMG:GB ratio and HDL cholesterol (Table either treatment (Fig. 1). After the first month, fasting
1). The post-methionine increase in tHcy at baseline tHcy had decreased from baseline by 4.17 0.59 mol/L
correlated inversely with plasma GB (r  0.37, P  on treatment A and by 4.9  1.3 mol/L on treatment
0.05) but not with B6, B12 or RBC folate concentrations. B (P  NS). The mean (95% CI) difference in fasting
tHcy between the treatments was 1.78 mol/L (1.17,Fasting plasma tHcy decreased to the same extent with
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Table 2. Fasting serum lipid concentrations on each treatment
Baseline Treatment A Treatment B
Total cholesterol 5.870.22 6.070.23a 5.660.18c
HDL cholesterol 1.260.08 1.350.07ac 1.290.08
LDL cholesterol 3.720.18 3.860.18a 3.500.17c
Total/HDL 5.120.26 4.890.26 4.830.27c
Triglycerides 1.980.17 2.010.18b 1.820.16c
Data are mean  SEM.
a P  0.001, b P  0.05 for treatments A vs. B
c P  0.05 compared to baseline
4.74). The increase in tHcy post-methionine was attenu-
ated with both treatments but was 18% less with treat-
ment A, where the increment in tHcy was 14.2  0.68
mol/L post-methionine, compared to 19.9 1.3mol/L
on treatment B (P  0.001 for both the increment and
the absolute tHcy level post-methionine; Fig. 1). The
mean (95% CI) difference in post-methionine tHcy con-
centrations was 6.02 mol/L (3.55, 8.49). Serum HDL
cholesterol, total cholesterol and triglyceride concentra-
tions were higher on treatment A than treatment B,
although the ratio of total:HDL cholesterol was similar
(Table 2).
Red blood cell folate and vitamin B6 concentrations
increased markedly in all patients, averaging 2482  203
nmol/L and 1021 190 nmol/L, respectively. Plasma GB
increased with treatment A from 29.3  2.1 mol/L to
392  34 mol/L (P  0.001), and promptly returned
to baseline values when patients switched treatments
(Fig. 2). Plasma DMG followed a similar pattern to GB,
increasing from 8.0  0.59 mol/L at baseline to a mean
of 55.1  8.4 mol/L on treatment A, and falling
promptly when GB was discontinued (Fig. 2). The ratio
of plasma DMG:GB did not change. Urinary concentra-
tions of GB and DMG both increased markedly with
betaine treatment (Fig. 2). There were no significant
Fig. 2. Plasma and urine concentrations of glycine betaine (GB) andcorrelations with the extent of decrease in either fasting
dimethylglycine (DMG) in group 1 (; N  19) and group 2 (;
or post-methionine tHcy levels. N  17). The increases with treatment A were highly significant: aP 
0.001 for plasma GB and DMG; bP  0.005 for urine GB; cP  0.01
for urine DMG.
DISCUSSION
The mechanism of hyperhomocysteinemia in chronic
renal failure is uncertain. Urinary excretion of homocys-
show that GB had no effect on fasting tHcy concentra-teine is trivial [13] and disturbances of the metabolic
tions, but it suppressed the increase in tHcy followingpathways of homocysteine are likely to be more impor-
the methionine load.tant. Folate is only partially effective at lowering tHcy
The risk of vascular disease from hyperhomocysteine-in patients with chronic renal failure, indicating that ab-
mia is associated with elevated tHcy in both the fastednormalities of other pathways are involved. Betaine-
state and after methionine loading [9]. The risk fromhomocysteine methyltransferase (BHMT), an enzyme
each form of hyperhomocysteinemia is of equal magni-found in liver and kidneys [14], utilizes glycine betaine
tude and independent, although both may occur together(GB) as a methyl donor to homocysteine in a reaction
[9]. In subjects with normal renal function impairmentthat yields methionine and N, N-dimethylglycine (DMG)
of remethylation causes elevated fasting tHcy, whereas(Fig. 3). The aim of this study was to determine whether
mild defects of transsulfuration are thought to be respon-dietary GB supplementation decreased tHcy concentra-
tions in patients with chronic renal failure. The results sible for elevated tHcy after methionine loading (Fig. 3)
McGregor et al: Betaine supplementation in CRF1044
Fig. 3. Betaine-homocysteine methyl transferase (BHMT) metabolic pathway. Glycine betaine (GB) is obtained from the diet or by conversion
of dietary choline. BHMT transfers a methyl group from GB to homocysteine, producing methionine and N,N-dimethylglycine, which is excreted
in urine or metabolized to sarcosine by dimethylglycine dehydrogenase. Abbreviations are: CBS, cystathionine -synthetase; MTHFR, N5,N10-
methylenetetrahydrofolate reductase.
[4]. Folate supplements decrease fasting, but not post- ous studies in dialysis patients found that GB did not
decrease fasting tHcy [21–23]. Methionine loading wasmethionine, plasma tHcy concentrations in normal indi-
viduals and in renal transplant recipients, whereas pyri- used in one of these studies, and also was unchanged
[21]. In contrast, our patients received the same dosedoxine only reduces post-methionine tHcy levels [15–18].
Fasting and post-methionine hyperhomocysteinemia of GB (4 g/day) but their post-methionine tHcy levels
decreased significantly. Our patients were not dialysishave been shown to coexist in chronic renal failure [19],
but the metabolic defects involved may differ from those dependent, however, and it is possible that a larger dose
of GB may be required in dialysis patients to achieve thefound in other patient groups. Van Guldener and col-
leagues reported recently that the transsulfuration path- same result. Folate/pyridoxine and GB both appeared to
decrease post-methionine tHcy in our patients, and theirway was intact in ESRD [20] and that folate supplements
decreased the post-methionine tHcy levels in hemodialy- effect was additive (Fig. 1). The clinical relevance of
reducing post-methionine tHcy levels to this extentsis patients [21]. Our study indicates that increasing activ-
ity in the BHMT pathway also ameliorates the response needs to be determined by further study.
A novel feature of this study is that we were able toto the methionine load. These data suggest that in
chronic renal failure, post-methionine hyperhomocys- measure plasma GB and DMG concentrations. Both
showed marked increases with GB supplementation,teinemia is not necessarily due to impaired transsulfura-
tion, and that disturbance of the remethylation pathways which confirmed that its bioavailability was high and
that the BHMT pathway was functional. Presumably,also may contribute.
This is the first study that we are aware of that has increased BHMT activity ameliorated the rise in tHcy
after methionine loading. It is interesting, therefore, thatexamined the effect of GB on fasting and post-methio-
nine tHcy in mild-moderate chronic renal failure. Previ- fasting tHcy concentrations were unchanged, since con-
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